News

Patients' Worry, Not Risk, Drives Double Mastectomies

View on the News

We Need to Educate Our Patients

The findings suggest that "we, as physicians, may not be adequately educating our patients about the risk for recurrent disease," said Dr. Jyoti D. Patel, who moderated the press conference.

In general, women with localized breast cancer in one breast have less than a 1% chance of developing a new cancer in the unaffected breast and an 8% chance of recurrence in the affected breast or a nearby lymph node. The risk for developing a new cancer in the contralateral breast rises to approximately 10%-15% if the patient has a history of breast or ovarian cancer in two or more primary relatives, with a similar or slightly greater increased risk from a positive genetic mutation, Dr. Patel estimated. Having both clinical risk factors confers a 10- to 20-fold increase in risk.

Dr. Jyoti Patel
Unfortunately, many women overestimate their risk of developing breast cancer in the contralateral breast and undergo unnecessary surgery, she commented. This study suggests that physicians re-examine how they communicate with their patients regarding the decision to undergo prophylactic mastectomy.

"Many women fear recurrence, and they also fear surveillance. They worry about, if they’re 35 years old, what a lifetime of screening for the contralateral breast might look like if they end up getting multiple biopsies. So how we put that in perspective for our young population will become vitally important," Dr. Patel said.

Dr. Patel, a thoracic oncologist at Northwestern University in Chicago, is a member of ASCO’s Cancer Communications Committee.


 

FROM A PRESS CONFERENCE SPONSORED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

"Many women fear recurrence, and they also fear surveillance. They worry about, if they’re 35 years old, what a lifetime of screening for the contralateral breast might look like if they end up getting multiple biopsies. So how we put that in perspective for our young population will become vitally important," said Dr. Patell, a thoracic oncologist at Northwestern University in Chicago and a member of ASCO’s Cancer Communications Committee.

Dr. Hawley reported having no financial disclosures.

Pages

Recommended Reading

Surgery for DCIS Saves Lives
MDedge Surgery
Radiofrequency Ablation Advances as Radiation Alternative in Breast Cancer
MDedge Surgery
SLN-Negative Breast Cancer Has Low Regional Recurrence
MDedge Surgery
AMA Delegates Slam PSA, Mammography Screening Recs
MDedge Surgery
DCIS Score Independently Predicts Ipsilateral Breast Events
MDedge Surgery
Radiation Therapy Beneficial Even for 'Good-Risk' Ductal Carcinoma
MDedge Surgery
FDA Panel Backs MarginProbe Breast Cancer Detection Device
MDedge Surgery
FDA Warns of QT Prolongation with Ondansetron Dose
MDedge Surgery
Cardiac Toxicity Not Seen 25 Years after Breast Radiation
MDedge Surgery
Screening Mammograms Overdiagnosed More Than 1 Million Women
MDedge Surgery